



# PROGRAM

## ANZGOG MEETINGS

### WEDNESDAY 29TH MARCH

Time	Session	Room
9.00am-10.45am	Tumour Type Working Group Meetings All TTWG Members gather in the Mayfair 1 for welcome prior to breakout to individual rooms. - Ovarian - Cervical - Endometrial	Mayfair 1 Mayfair 2 Mayfair 3
10.45am - 11.00am	Morning Tea	Mayfair Foyer
11.00am - 12.30pm	Research Advisory Committee Meeting I	Mayfair 1
12.30pm - 1.30pm	Lunch	Mayfair Foyer
12.30pm - 3.00pm	ANZGOG Board of Directors Meeting	Grosvenor 1 & 2

## SOCIAL PROGRAM

### Welcome Reception: Bus Departs Grand Hyatt at 6.00pm

Wednesday, 29th March | 6.30pm - 9.00pm

Peter MacCallum Cancer Centre

305 Grafton Street, Melbourne

### Conference Dinner

Friday, 31st March | 7.00pm - 11.00pm

The Residence Grand Hyatt



## PURE SCIENCE SYMPOSIUM PROGRAM

WEDNESDAY 29TH MARCH

Time	Session	
1.30pm - 3.00pm	<b>PURE SCIENCE SYMPOSIUM</b> Session Chairs: Pam Pollock and Elaine Sanij Mayfair 1	<b>GCP TRAINING</b> Session Chair: Sue Brew Mayfair 2
1.30pm - 1.50pm	<b>Kirsty Pringle</b> <i>Novel insights into the renin-angiotensin system in endometrial cancer</i>	<p>Learn about the first change to GCP since its debut in 1996.</p> <p>Presenter: Eleanor Allan GCP Training Caledonian Clinical Training</p> <p>Bi-Annual Update Certificate Training For Study Coordinators, Nurses, Clinicians.</p>
1.50pm - 2.10pm	<b>Liz Christie</b> <i>Characterizing acquired chemoresistance in HGSC</i>	
2.10pm - 2.30pm	<b>Clare Scott</b> <i>Response and Resistance to PARP inhibitors: Beyond BRCA1/2</i>	
2.30pm - 2.40pm	<b>Tracey O'Mara</b> <i>Meta-analysis of genome-wide association data for 78,683 women by the Endometrial Cancer Association Consortium (ECAC) identifies eight new genetic risk regions for endometrial cancer</i>	
2.40pm - 2.50 pm	<b>Claire Henry</b> <i>Distinct patterns of expression of ROR1 and ROR2 in histological subtypes of epithelial ovarian cancer point to a role for the stroma in metastasis</i>	
2.50pm - 3.00pm	Q&A or Panel	
3.00pm - 3.30pm	Afternoon Tea	
3.30pm - 5.00pm	<b>PURE SCIENCE SYMPOSIUM</b> Session Chairs: Clare Scott and Nikola Bowden Mayfair 1	<b>GCP TRAINING</b> Presenter: Eleanor Allan Mayfair 2
3.20pm - 3.40pm	<b>Caroline Gargett</b> <i>Stem/progenitor cells in the normal endometrium and endometrial cancer</i>	
3.40pm - 4.00pm	<b>Kylie Gorringe</b> <i>Exploring the genomic landscape of mucinous ovarian tumours</i>	
4.00pm - 4.20pm	<b>Susan Jordan</b> <i>Pooled analyses from the Epidemiology of Endometrial Cancer Consortium (E2C2): how do breast feeding and NSAID use influence endometrial cancer risk?</i>	
4.20pm - 4.30pm	<b>Yu Yu</b> <i>Syk activity determines invasiveness and its nuclear level is associated with poor survival in Ovarian Cancer</i>	
4.30pm - 4.50pm	<b>Jason Lee</b> <i>Inhibition of histone methyltransferases as novel targets for ovarian cancer therapy</i>	

## CONFERENCE PROGRAM

### THURSDAY 30TH MARCH

Time	Session
6.45am - 7.45am	Consumer led <b>Health and Fitness Session</b> 'Go step for Gynae' – gather in hotel outdoor forecourt, next to Reception.
8.30am - 8.45am	<b>OFFICIAL WELCOME &amp; ANZGOG UPDATE</b> <b>ALISON BRAND</b> Savoy 1
8.45am - 10.00am	<b>MAKING A DIFFERENCE FOR WOMEN WITH GYNAECOLOGICAL CANCER</b> Session Chairs: Peter Sykes & Pearly Khaw Savoy 1
8.45am - 9.10am	<b>Anil Sood</b> <i>A framework for personalized approaches to ovarian cancer</i>
9.10am - 9.35am	<b>David Tan</b> <i>Ovarian clear cell carcinomas: Challenges and opportunities</i>
9.35am - 10.00am	<b>Remi Nout</b> <i>Combined modality treatment in rare gynaecological cancers</i>
10.00am - 10.30am	Morning Tea in the Exhibition Area
10.30am - 12.00pm	<b>IMPROVING CLINICAL PRACTICE FOR WOMEN WITH CANCER</b> Session Chairs: Sumi Ananda & Deb Neesham Savoy 1
10.30am - 10.50am	<b>Kate Stern</b> <i>Improving clinical practice in fertility preservation</i>
10:50am – 11.10am	<b>Bradley Monk</b> <i>International Game changing clinical trials- present and future</i>
11.10am - 11.30am	<b>George Au-Yeung</b> <i>Immunotherapy- promise, potential and pitfalls</i>
11.30am - 11.45am	<b>Paul Cohen</b> <i>Prognostic role of histologic tumour regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma</i>
11.45am - 12.00pm	<b>Linda Mileshkin</b> <i>Incidence of hypersensitivity reactions to paclitaxel with intravenous versus oral dexamethasone pre-medication</i>
12.00pm - 1.00pm	Lunch - Consumer Committee Bristol 1 / Quality Assurance Bristol 2/ Study Coordinators Connaught



# CONFERENCE PROGRAM

THURSDAY 30TH MARCH

Time	Session
1.00pm - 2.30pm	<b>TRIAL UPDATE</b> Session Chairs: Linda Mileshkin, RAC Chair, Alison Davis, RAC Dep Chair Savoy 1 1. PARAGON- PI Michael Friedlander 2. OUTBACK- PI Linda Mileshkin 3. REZOLVE- PI Katrin Sjoquist 4. ECHO- PI Sandi Hayes presented by Martin Stockler 4. FEMME- PI Andreas Obermair presented by Vanessa Taylor 5. VELIA- PI Michael Friedlander 6. MOST- PI Michael Friedlander 7. PHAEDRA- PI Yoland Antill 8. STATEC- PI Alison Brand
2.30pm - 3.00pm	Afternoon Tea
3.00pm-4.00pm	<b>REDUCING THE CANCER BURDEN</b> Session Chairs: Peter Grant & Christopher Steer Savoy 1 Sponsored by: 
3.00pm - 3.20pm	<b>Lisa Whop</b> <i>Reducing the cancer burden in ATSC population</i>
3.20pm – 3.40pm	<b>Julia Brotherton</b> <i>Leading the cervical cancer prevention revolution: Australia's new cervical screening approach in the HPV vaccine eras</i>
3.40pm – 4.00pm	<b>Rob Thomas</b> <i>Cancer Pathway Development in Australia, Cancer Chief Advisor VIC Govt</i>
4.00pm – 4.30pm	<b>OASIS PROGRAM TRIAL UPDATE</b> Session Chairs: Michael Friedlander And Anna Defazio Savoy 1
4.00pm – 4.10pm	1. MOCCA- PI Michael Friedlander
4.10pm – 4.20pm	2. VIPS- PI Linda Mileshkin
4.20pm – 4.30pm	3. CYCLIN-E1- PI Danny Rischin
4.30pm - 5.00pm	<b>TRANSLATIONAL ANZGOG   TR-ANZGOG</b> Session Chairs: Michael Friedlander And Anna Defazio
4.30pm – 5.00pm	<b>Anna Defazio</b> <i>More than a biobank!</i> <i>Enabling translational research for ANZGOG trials</i>
5.00pm – 5.45pm	Poster Viewing Session
5.45pm - 6.45pm	<b>ANZGOG EVENING SESSION</b> Session Chair: Michael Friedlander Practical guidance on the use of OLAPARIB in women with PSR BRCAM HGSO <b>Michael Friedlander, Linda Mileshkin, Catherine Shannon</b>
Evening Options	Free evening for dinner with friends and colleagues in Melbourne

## CONFERENCE PROGRAM

### FRIDAY 31ST MARCH

Time	Session
7.00am - 8.00am	<b>ROCHE BREAKFAST: SATELLITE SYMPOSIUM</b> <b>IMPROVING OUTCOMES IN HGSOC: FROM TARGETED TRIALS TO TARGETED THERAPIES</b> Chair: Dr George Au-Yeung, Peter MacCallum Cancer Centre The Speakers: Prof Rob Coleman MD Anderson and Prof Bradley Monk, University of Arizona Cancer Centre Savoy 3
8.30am - 10.15am	<b>IMPROVING QUALITY OF LIFE</b> Session Chairs: Sue Brew & Catherine Adams Savoy 1
8.30am - 9.45am	<i>Panel Session addressing 2 cases studies on Improving Quality of Life</i> <b>Dr Janine Lombard</b> – Calvary Mater Newcastle, <b>Dr Viet Do</b> – Westmead Hospital, <b>Julia Martin</b> – John Hunter Hospital, <b>Kim Hobbs</b> – Westmead Hospital <b>Dr Bryony Simcock</b> – Christchurch
9.45am - 10.00am	<b>Penelope Webb</b> <i>Lifestyle, side-effects and chemotherapy completion: results from the Ovarian Cancer Prognosis and Lifestyle (OPAL) Study</i>
10.00am - 10.15am	<b>Yeh Chen Lee</b> <i>The Risk of Endometrial Cancer for BRCA1 and BRCA2 Mutation Carriers</i>
10.15am - 10.45am	Morning Tea in the Exhibition Area
10.45am - 11.00am	<b>Helene O'Neill and Consumer Group Presentation</b>
11.00am - 1.00pm	<b>TRIAL CONCEPTS</b> Session Chairs: Linda Mileshkin & Alison Davis Savoy 1
11.00am - 11.15am	<b>Rob Rome</b> <i>Progress towards the establishment of an Australian Ovarian Cancer Clinical Quality Registry</i>
11.15am - 11.25am	<b>Michael Friedlander (PI Linda Mileshkin)</b> <i>Trials in Development- ICON 9</i>
11.25am - 11.35am	<b>PI Kelly Phillip, Chen Lee</b> <i>Trials in Development- STICS AND STONES (just received NHMRC Grant)</i>
11.35am - 11.45am	<b>PI Linda Mileshkin</b> <i>Trials in Development- Advaxis AIM2CERV</i>
11.45am - 11.50am	Questions
11.50am - 12.05pm	<b>Tarek Meniawy</b> <i>NEW CONCEPT 1: A phase II study of a PD-1/PD-L1 blockade in combination with neoadjuvant chemotherapy in newly diagnosed advanced ovarian cancer</i>
12.05pm - 12.20pm	<b>Martha Hickey</b> <i>NEW CONCEPT 2: WHAM (What Happens after Menopause)? Impact of risk-reducing bilateral salpingo-oophorectomy on non-cancer outcomes in high-risk women: A multicentre prospective study</i>
12.20pm - 12.35pm	<b>Rachel Delahunty</b> <i>NEW CONCEPT 3: Assessing Circulation Tumour DNA as a Predictive Biomarker in Type 2 Endometrial Cancer</i>
12.35pm - 12.50pm	<b>Danny Rischin</b> <i>NEW CONCEPT 4: Vascular disruption, anti-angiogenesis and immune checkpoint inhibition in high grade serous ovarian cancer</i>
12.50pm - 1.00pm	<i>NEW CONCEPTS: Questions and Discussion</i>
1.00pm - 2.00pm	Lunch in the Exhibition Area / STATEC Trial Meeting Connaught







Time	Session		
2.00pm - 5.00pm	<b>SPECIALISED PROGRAM</b>		
2.00pm – 3.30pm	<b>Workshop 1:</b> Concept Development Savoy 1	<b>Workshop 2:</b> Gynae Nurses Savoy 2	<b>Workshop 3:</b> Radiation Oncology  Savoy 3
	<b>Workshop 4:</b> Consumers Bristol 1	<b>Workshop 5:</b> Study Coordinators Bristol 2	STATEC - Lymphedema Training Connaught
3.30pm - 4.00pm	Afternoon Tea		
4.00pm - 5.30pm	<b>Workshop 1:</b> Concept Development Savoy 1	<b>Workshop 2:</b> Gynae Nurses Savoy 2	<b>Workshop 3:</b> Radiation Oncology Savoy 3
	<b>Workshop 4:</b> Consumers Bristol 1	<b>Workshop 5:</b> Study Coordinators Bristol 2	PHAEDRA - trial meeting Connaught

## CONFERENCE PROGRAM

### SATURDAY 1ST APRIL

Time	Session
7.00am - 8.30am	RAC 2 Breakfast meeting Mayfair 2
8.45am - 10.15am	<b>NEW HORIZONS - BENCH TO BEDSIDE</b> Session Chairs: Paul Cohen & Jeff Goh Mayfair 1
	Sponsored by: 
8.45am - 9.05am	<b>David Tan</b> <i>Gene expression molecular subtypes in ovarian cancer: the next stop for precision medicine?</i>
9.05am - 9.25am	<b>Anil Sood</b> <i>Targeting the Undruggable: Advances and Obstacles in RNAi Therapy</i>
9.25am - 9.45am	<b>Remi Nout</b> <i>Introducing molecular prognostic factors for endometrial cancer into clinical practice - the PORTEC4a experience.</i>
9.45am - 10.00am	<b>Tarek Meniawy</b> <i>Higher PD-L1 expression predicts poor prognosis in patients with tubo-ovarian high-grade serous carcinoma treated with neoadjuvant chemotherapy</i>
10.00am - 10.15am	<b>Nirmala Kampan</b> <i>Serum IL-6 as a predictive biomarker for diagnosis of malignancy in high-grade serous ovarian carcinoma</i>
10.15am - 10.45am	Morning Tea in the Exhibition Area
10.45am - 11.45am	<b>DEVELOPING STUDIES AND FUNDING WITH ANZGOG</b> Session Chairs: Alison Brand & Raj Ali Mohan Mayfair 1
	Sponsored by: 
10.45am - 11.00am	<b>Alison Brand</b> <i>Developing Studies and Funding Options through ANZGOG</i>
11.00am - 11.10am	<b>Philip Beale</b> <i>Ovarian TTWG</i>
11.10am - 11.20am	<b>Diana Adams</b> <i>Endometrial TTWG</i>
11.20am - 11.30am	<b>Anne Hamilton</b> <i>Cervix TTWG</i>
11.30am - 11.45am	<b>Peter Sykes</b> <i>A review of cervical cancer cares in relation to screening history in New Zealand from 2008-2012</i>
11.45am - 12.45pm	<b>DEBATE: SURGERY IS THE ULTIMATE SOLUTION TO ALL GYNAECOLOGICAL CANCER PROBLEMS</b> Session Chairs: Alison Brand & Raj Ali Mohan <b>Rob Coleman &amp; Julie Lamont (affirmative) V Pearly Khaw &amp; Andrew Dean (negative)</b> Mayfair 1
12.45pm - 12.50pm	Thank you to delegates – ANZGOG Chair, Alison Brand
12.50pm - 1.30pm	Light Lunch available ( <i>Buses depart from 1.30pm to Airport</i> )





## CONSUMER EVENT

SATURDAY 1ST APRIL

Time	Session
2.00pm - 4.30pm	<b>CONSUMER INFORMATION SESSION</b> Collaborative Presentation by Ovarian Cancer Australia and ANZGOG Mayfair 1
	<i>Introduction</i>
	<b>Tarek Meniawy</b> <i>Immunotherapy as an Ovarian Cancer Treatment</i>
3.05pm - 3.30pm	Q & A
	Afternoon Tea
	<b>Emma Burt</b> <i>Participating in a Clinical Trial:</i>
	<b>Linda Mileskin</b> <i>Finding New Cancer Treatments &amp; the Importance of Clinical Trials</i>
	Q & A
	<b>Bronwyn Grout</b> <i>Survivors Teaching Students: Saving Women's Lives</i>